Further experience with rezoxane (ICRF 159; -- NSC --129943) in treating Kaposi's sarcoma.
47 patients with histologically proven Kaposi's sarcoma were treated with multiple courses of Rezoxane (each course: 1 g/m2/day for 3 days) orally. The overall response was 57% with 20% achieving complete response. The median remission duration of the complete responders is 12 months (range 2--26) with 6 still having sustained complete remissions. Most of the responders were patients with nodular mixed type of Kaposi's sarcoma. The toxicity was minimal and was mainly leukopenia, alopecia and gastrointestinal disturbance. Rezoxane is a useful safe drug and easy to administer to patients with Kaposi's sarcoma.
D000293:Adolescent; D000328:Adult; D000368:Aged; D002648:Child; D005260:Female; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000627:therapeutic use*; D011929:Razoxane / Q000009:adverse effects / Q000627:therapeutic use*; D012075:Remission, Spontaneous; D012514:Sarcoma, Kaposi / Q000188:drug therapy*; D013997:Time Factors
D010879:Piperazines; D011929:Razoxane